What is the molecular diagnostics cancer market size?

The molecular diagnostics cancer market size is approximately USD 2.5 billion as of 2022.

What is the growth forecast for the molecular diagnostics cancer market?

The market is expected to grow at a CAGR of 7.1% from 2023 to 2028.

What are the key drivers of the molecular diagnostics cancer market?

Increasing cancer prevalence and advancements in genetic testing drive the molecular diagnostics cancer market.

What are the major challenges facing the molecular diagnostics cancer market?

High costs and limited reimbursement policies hinder the molecular diagnostics cancer market growth.

Which regions are leading the molecular diagnostics cancer market?

North America and Europe are the leading regions in the molecular diagnostics cancer market.

Who are the top companies in the molecular diagnostics cancer market?

Leading companies include Roche, Abbott, and Illumina, driving innovation and growth.

What future opportunities exist in the molecular diagnostics cancer market?

Emerging technologies and expanding applications in developing countries offer future outlook opportunities.

How does technology impact the molecular diagnostics cancer market?

Advances in next-generation sequencing and artificial intelligence enhance the molecular diagnostics cancer market.

What is the regulatory landscape for the molecular diagnostics cancer market?

Stringent regulations and standards from FDA and CE mark impact the molecular diagnostics cancer market.

What is the future outlook for the molecular diagnostics cancer market?

The market is expected to experience significant growth due to increasing demand for personalized medicine.

What Is the Global molecular diagnostics cancer Market Worth in 2026?

molecular diagnostics cancer by Application (Respiratory Cancer, Cancer of Digestive System, Cancer of Urinary System, Cancer of Circulatory System, Motor System Cancer, Reproductive System Cancer, Other), by Types (Pharmacogenomic Diagnosis, Liquid Biopsy, Other) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

molecular diagnostics cancer Market Size | CAGR 10.2 Forecast 2033

What Is the Global molecular diagnostics cancer Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

molecular diagnostics cancer Market Overview

The molecular diagnostics cancer market is a crucial segment of the healthcare industry, focusing on the diagnosis and treatment of cancer through molecular biology techniques. As the global healthcare landscape continues to evolve, the molecular diagnostics cancer market size is estimated to be around $8.4 billion in 2025, with a growth outlook that is highly promising. The market forecast suggests a significant expansion, driven by factors such as increasing cancer prevalence, advancements in technology, and rising demand for personalized medicine. The industry expansion is expected to be fueled by a compound annual growth rate (CAGR) of around 13.4% from 2026 to 2033, with key drivers including liquid biopsy, next-generation sequencing, and precision medicine.

Loading chart…

The molecular diagnostics cancer market is shaped by several key forces, including technology shifts, such as the adoption of artificial intelligence and machine learning, regulatory frameworks that govern the approval and use of molecular diagnostics, and consumer behavior, driven by increasing awareness and demand for personalized healthcare. The largest region in the molecular diagnostics cancer market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing investments in healthcare infrastructure and a growing demand for cancer diagnostics. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends, drivers, and challenges shaping the molecular diagnostics cancer market.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Roche; Danaher; Siemens Healthineers; Abbott Laboratories; ICON Plc; AstraZeneca; MDxHealth; Invitae; PlexBio; Thermo Fisher Scientific; Guardant Health; Biocartis; Bio-Techne; Merck; Foundation Medicine; 10X Genomics; Biodesix; CytoTrack; GenomOncology; Luminex
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The molecular diagnostics cancer market is poised for significant growth, driven by technological advancements, increasing cancer prevalence, and a rising demand for personalized medicine. This section explores the key dynamics shaping the market, including growth drivers, restraints, opportunities, and challenges that will influence the molecular diagnostics cancer market size and growth forecast.

Growth Drivers2 items

Advances in next-generation sequencing and liquid biopsy technologies are expanding the range of cancer biomarkers that can be detected, enabling earlier diagnosis and more targeted treatment. This, in turn, is driving growth in the molecular diagnostics cancer market.

Government initiatives and funding for cancer research are increasing, leading to a greater understanding of the genetic basis of cancer and the development of more effective molecular diagnostics tests.

Restraints2 items

High development costs and the need for significant investment in research and development are limiting the entry of new players into the molecular diagnostics cancer market and constraining the growth forecast of existing companies.

Stringent regulatory requirements and the need for clinical validation of new tests are creating barriers to market entry and slowing the adoption of innovative molecular diagnostics technologies.

Opportunities2 items

The growing demand for precision medicine and personalized cancer treatment is creating opportunities for companies to develop targeted molecular diagnostics tests that can help guide therapy selection and improve patient outcomes.

Emerging markets in Asia-Pacific and Latin America offer significant growth potential for molecular diagnostics cancer market players, driven by increasing cancer prevalence, expanding healthcare infrastructure, and rising demand for advanced diagnostic technologies.

Challenges2 items

The molecular diagnostics cancer market is highly competitive, with many established players and new entrants competing for market share. This competition is driving down prices and making it challenging for companies to maintain profitability.

The integration of artificial intelligence and machine learning into molecular diagnostics workflows is creating new challenges related to data management, cybersecurity, and the need for specialized expertise.

Market Segmentation

Loading chart…

The molecular diagnostics cancer market can be segmented based on application, which includes oncology and liquid biopsy. The oncology segment is further divided into subtypes such as breast cancer, lung cancer, and colorectal cancer. Each of these subtypes contributes to the overall molecular diagnostics cancer market size, with the breast cancer segment being the largest contributor. Understanding the molecular diagnostics cancer segmentation is crucial for market players to develop effective strategies and tap into the growing demand for molecular diagnostics in cancer treatment.

Another way to segment the molecular diagnostics cancer market is by types, which includes polymerase chain reaction (PCR), next-generation sequencing (NGS), and in situ hybridization (ISH). The PCR segment holds the largest market share due to its high sensitivity and specificity. The NGS segment is expected to grow at a rapid pace due to its ability to analyze multiple genes simultaneously. The molecular diagnostics cancer market taxonomy reveals that each type has its own strengths and weaknesses, and market players must carefully consider these factors when developing their products and services.

molecular diagnostics cancer Segmentation Breakdown12 items

Application

Respiratory Cancer

Cancer of Digestive System

Cancer of Urinary System

Cancer of Circulatory System

Motor System Cancer

Reproductive System Cancer

Other

Types

Pharmacogenomic Diagnosis

Liquid Biopsy

Other

Regional Insights

Loading chart…

The molecular diagnostics cancer market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of advanced diagnostic technologies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high infrastructure development, and a large patient population. In Europe, drivers include a strong regulatory framework, increasing demographics of cancer patients, and a high level of ecosystem maturity. Asia Pacific is driven by rapid urbanization, a large and growing population, and increasing access to healthcare services. Latin America and Middle East & Africa are driven by growing awareness of cancer, improving infrastructure, and increasing government initiatives to enhance healthcare services.

The regional forecast indicates that Asia Pacific will experience the highest molecular diagnostics cancer market growth, driven by emerging economies such as China and India. Latin America and Middle East & Africa are also expected to experience significant growth, driven by increasing demand for diagnostic services and improving healthcare infrastructure.

Competitive Landscape

The molecular diagnostics cancer competitive landscape is moderately consolidated, with a mix of global players and local/regional companies. The market is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Understanding the molecular diagnostics cancer competitive landscape is crucial for companies to navigate the market effectively. Global players are focusing on product innovation and regulatory approvals to stay ahead, while local companies are leveraging their distribution networks and pricing strategies to compete.

Companies in the molecular diagnostics cancer market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To overcome these challenges, companies are focusing on technology, service model, channel strength, customization, and cost advantages to differentiate themselves. The following companies are pursuing different strategic focuses:

Roche: regional expansion

Danaher: innovation pipeline

Siemens Healthineers: premium pricing

Abbott Laboratories: vertical integration

Thermo Fisher Scientific: OEM tie-ups

Guardant Health: local manufacturing

Key molecular diagnostics cancer Companies20 items

Roche

Danaher

Siemens Healthineers

Abbott Laboratories

ICON Plc

AstraZeneca

MDxHealth

Invitae

PlexBio

Thermo Fisher Scientific

Guardant Health

Biocartis

Bio-Techne

Merck

Foundation Medicine

10X Genomics

Biodesix

CytoTrack

GenomOncology

Luminex

Market Ecosystem

The molecular diagnostics cancer ecosystem spans upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value creation and capture occur as technology providers supply essential components, integrators develop testing solutions, and channels deliver these solutions to end users, such as laboratories and hospitals. The molecular diagnostics cancer ecosystem is characterized by a complex interplay of participants, each contributing to the development, manufacturing, and deployment of diagnostic tests.

Raw material/component suppliers — provide chemical reagents

Technology providers — develop diagnostic testing platforms

OEMs / manufacturers — produce diagnostic equipment

System integrators / EPCs — integrate testing solutions

Distributors / channel partners — deliver diagnostic tests

Regulators/standards bodies — establish testing guidelines

End users / buyers — utilize diagnostic tests for patient care

Within the molecular diagnostics cancer ecosystem, control points, such as regulatory approvals and reimbursement policies, influence adoption rates. Dependency risks, including input constraints and standards compliance, can also impact the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements may affect the relationships between ecosystem participants. A thorough value chain analysis is necessary to understand these dynamics and how they vary by region, as the molecular diagnostics cancer ecosystem differs significantly across diverse geographic areas.

Recent Industry Insights

The molecular diagnostics cancer industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and diagnostic manufacturers, have accelerated the development of innovative cancer detection technologies. Furthermore, the industry has seen notable mergers and acquisitions, with major players expanding their portfolios to include cutting-edge molecular diagnostic solutions.

Additionally, there have been several product launches and technology introductions, including next-generation sequencing platforms and liquid biopsy tests. Regulatory changes, such as updated guidelines for diagnostic test approval, have also impacted the molecular diagnostics cancer industry. The shift in consumer or enterprise trends towards personalized medicine has driven the demand for molecular diagnostics, leading to increased funding rounds and expansions in the industry.

Analyst Overview

As the Lead Analyst, my expert view on the molecular diagnostics cancer market is that it presents a highly attractive opportunity for growth, driven by increasing demand for personalized medicine and precise diagnostics. The competitive intensity is moderate, with key players investing heavily in research and development to improve the molecular diagnostics cancer market outlook. Looking ahead, the long-term outlook is promising, with innovations in next-generation sequencing and artificial intelligence expected to drive growth.

The innovation landscape is rapidly evolving, with a focus on developing more sensitive and specific tests. However, the demand-supply balance is a key risk factor, as the market may face challenges in meeting the growing demand for molecular diagnostics. Overall, the molecular diagnostics cancer market is poised for significant growth, but companies must navigate these challenges to capitalize on the opportunity.

11 items

1. Executive Summary

2. molecular diagnostics cancer Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global molecular diagnostics cancer Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global molecular diagnostics cancer Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Respiratory Cancer

6.1.2. Cancer of Digestive System

6.1.3. Cancer of Urinary System

6.1.4. Cancer of Circulatory System

6.1.5. Motor System Cancer

6.1.6. Reproductive System Cancer

6.1.7. Other

6.2. Global molecular diagnostics cancer Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Pharmacogenomic Diagnosis

6.2.2. Liquid Biopsy

6.2.3. Other

6.3. Global molecular diagnostics cancer Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global molecular diagnostics cancer Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global molecular diagnostics cancer Market by: Regions (Value)

8. Global molecular diagnostics cancer Market Competition by Key Manufacturers

8.1. Global molecular diagnostics cancer Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global molecular diagnostics cancer: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Danaher

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Siemens Healthineers

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbott Laboratories

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. ICON Plc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. AstraZeneca

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. MDxHealth

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Invitae

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. PlexBio

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Thermo Fisher Scientific

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Guardant Health

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Biocartis

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Bio-Techne

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Merck

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Foundation Medicine

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. 10X Genomics

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Biodesix

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. CytoTrack

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. GenomOncology

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Luminex

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global molecular diagnostics cancer Market

Figure 4: Global molecular diagnostics cancer Market: Drivers

Figure 5: Global molecular diagnostics cancer Market: Challenges

Figure 6: Global molecular diagnostics cancer Market: Trends

Figure 7: Global molecular diagnostics cancer Market: Opportunity

Figure 8: Global molecular diagnostics cancer Market: Restraint

Figure 9: Global molecular diagnostics cancer Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global molecular diagnostics cancer Market Value (USD Million) By Region

Figure 15: Global molecular diagnostics cancer Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global molecular diagnostics cancer Market Value (USD Million) By Region

Figure 23: Global molecular diagnostics cancer Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global molecular diagnostics cancer Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global molecular diagnostics cancer Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global molecular diagnostics cancer Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global molecular diagnostics cancer Market Value (USD Million) By Region

Table 10: Global molecular diagnostics cancer Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global molecular diagnostics cancer Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global molecular diagnostics cancer Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global molecular diagnostics cancer Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: Danaher Basic Information And Sales Area

Table 33: Danaher. Products Portfolio

Table 34: Siemens Healthineers Basic Information And Sales Area

Table 35: Siemens Healthineers. Products Portfolio

Table 36: Abbott Laboratories Basic Information And Sales Area

Table 37: Abbott Laboratories. Products Portfolio

Table 38: ICON Plc Basic Information And Sales Area

Table 39: ICON Plc. Products Portfolio

Table 40: AstraZeneca Basic Information And Sales Area

Table 41: AstraZeneca. Products Portfolio

Table 42: MDxHealth Basic Information And Sales Area

Table 43: MDxHealth. Products Portfolio

Table 44: Invitae Basic Information And Sales Area

Table 45: Invitae. Products Portfolio

Table 46: PlexBio Basic Information And Sales Area

Table 47: PlexBio. Products Portfolio

Table 48: Thermo Fisher Scientific Basic Information And Sales Area

Table 49: Thermo Fisher Scientific. Products Portfolio

Table 50: Guardant Health Basic Information And Sales Area

Table 51: Guardant Health. Products Portfolio

Table 52: Biocartis Basic Information And Sales Area

Table 53: Biocartis. Products Portfolio

Table 54: Bio-Techne Basic Information And Sales Area

Table 55: Bio-Techne. Products Portfolio

Table 56: Merck Basic Information And Sales Area

Table 57: Merck. Products Portfolio

Table 58: Foundation Medicine Basic Information And Sales Area

Table 59: Foundation Medicine. Products Portfolio

Table 60: 10X Genomics Basic Information And Sales Area

Table 61: 10X Genomics. Products Portfolio

Table 62: Biodesix Basic Information And Sales Area

Table 63: Biodesix. Products Portfolio

Table 64: CytoTrack Basic Information And Sales Area

Table 65: CytoTrack. Products Portfolio

Table 66: GenomOncology Basic Information And Sales Area

Table 67: GenomOncology. Products Portfolio

Table 68: Luminex Basic Information And Sales Area

Table 69: Luminex. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global molecular diagnostics cancer Market Value (USD Million) By Region

Table 75: Global molecular diagnostics cancer Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

molecular diagnostics cancer Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Roche; Danaher; Siemens Healthineers; Abbott Laboratories; ICON Plc; AstraZeneca; MDxHealth; Invitae; PlexBio; Thermo Fisher Scientific; Guardant Health; Biocartis; Bio-Techne; Merck; Foundation Medicine; 10X Genomics; Biodesix; CytoTrack; GenomOncology; Luminex
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options